Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia
NCT05815485 is registered in ClinicalTrials.gov with The University of Texas Medical Branch, Galveston as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Phase
- Phase 2/3
- Overall status
- Active, not recruiting
- Start date
- May 4, 2023
- Completion date
- April 30, 2026
- Enrollment
- 144 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.